Factors associated with immunological non-response after ART initiation: a retrospective observational cohort study

[1]  Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic Review: Erratum. , 2020, Journal of acquired immune deficiency syndromes.

[2]  Mardge H. Cohen,et al.  Genetic and clinical predictors of CD4 lymphocyte recovery during suppressive antiretroviral therapy: Whole exome sequencing and antiretroviral therapy response phenotypes , 2019, PloS one.

[3]  N. V. Trung,et al.  Long‐term viral suppression and immune recovery during first‐line antiretroviral therapy: a study of an HIV‐infected adult cohort in Hanoi, Vietnam , 2017, Journal of the International AIDS Society.

[4]  A. d’Arminio Monforte,et al.  CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. , 2015, The lancet. HIV.

[5]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[6]  S. Lucas,et al.  HIV and the spectrum of human disease , 2015, The Journal of pathology.

[7]  Kholoud Porter,et al.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy , 2014, AIDS.

[8]  B. Gazzard,et al.  CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE , 2012, PLoS medicine.

[9]  M. Kamya,et al.  High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort , 2011, BMC infectious diseases.

[10]  S. Leone,et al.  CD4+ T lymphocyte recovery in individuals with type 1 human immunodeficiency virus infection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Ray Y. Chen,et al.  Cohort profile: the Chinese national free antiretroviral treatment cohort. , 2010, International journal of epidemiology.

[12]  M. Leal,et al.  Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. , 2009, Current HIV research.

[13]  A. Mocroft,et al.  Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression , 2009, Journal of acquired immune deficiency syndromes.

[14]  G. Luzi,et al.  Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Neaton,et al.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection , 2008, AIDS.

[16]  M. Muñoz-Fernández,et al.  Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency. , 2008, The Journal of infection.

[17]  Richard D Moore,et al.  CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[19]  M. Battegay,et al.  Immunological recovery and antiretroviral therapy in HIV-1 infection. , 2006, The Lancet. Infectious diseases.

[20]  Fernando Aiuti,et al.  Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. , 2006, AIDS reviews.

[21]  A. Aiuti,et al.  Immunodysregulation of HIV disease at bone marrow level. , 2005, Autoimmunity reviews.

[22]  M. Miller,et al.  Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Battegay,et al.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Felipe García,et al.  Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count , 2004, Journal of acquired immune deficiency syndromes.

[25]  E. Ruiz-Mateos,et al.  Thymic volume is associated independently with the magnitude of short‐ and long‐term repopulation of CD4+ T cells in HIV‐infected adults after highly active antiretroviral therapy (HAART) 1 , 2004, Clinical and experimental immunology.

[26]  M. Lederman,et al.  Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy , 2003, AIDS.

[27]  O. Kirk,et al.  Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study , 2003, HIV medicine.

[28]  M. Leal,et al.  T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. , 2002, Blood.

[29]  A. Mocroft,et al.  Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. , 2001, The Journal of infectious diseases.

[30]  E. Ruiz-Mateos,et al.  Baseline Thymic Volume is a Predictor for CD4 T Cell Repopulation in Adult HIV-Infected Patients under Highly Active Antiretroviral Therapy , 2001, Antiviral therapy.

[31]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.

[32]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[33]  B. Blom,et al.  Early stages in the development of human T, natural killer and thymic dendritic cells , 1998, Immunological reviews.

[34]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[35]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[36]  M. Lederman,et al.  Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. , 2000, The Journal of infectious diseases.